Biotech | September 23, 2021
Aurobindo subsidiary submits MAA for oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
The partnership is a significant step in delivering advanced cancer therapies to patients.
About 250+ women riders participate in the awareness ride where free breast screening camp were conducted
The company said the safety profile remained consistent with earlier studies and was considered manageable
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
